Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics (MLTX), sold 17,876 shares at $19.68 ($352K) on 2026-06-17, disclosed to the SEC on 2026-06-18.
Scheduled sale ($352k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.68 | 15,082 | $297K | 84.4% |
| 2 | $19.60 | 2,794 | $55K | 15.6% |
| Total | $19.67 avg | 17,876 | $352K | 100% |
| Filing → |
| MLTX | SELL | 2026-04-16 | $47K | — | Filing → |
| MLTX | SELL | 2026-04-10 | $1.7M | — | Filing → |
| MLTX | BUY | 2025-10-09 | $198K | — | Filing → |